Trials / Conditions / 22q11.2 Deletion Syndrome

22q11.2 Deletion Syndrome

13 registered clinical trials studyying 22q11.2 Deletion Syndrome — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromos NCT07493096	Healing Hope International	—
Recruiting	Early Scoliotic Changes in Children at Increased Risk for Scoliosis Development NCT05924347	UMC Utrecht	—
Recruiting	Understanding of Psychotic Disorders in Children With 22q11.2DS NCT04639388	Hôpital le Vinatier	N/A
Terminated	Arithmetic Abilities in Children With 22q11.2DS NCT04373226	Hôpital le Vinatier	N/A
Completed	Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion NCT05149898	Harmony Biosciences Management, Inc.	Phase 2
Terminated	Social Cognition Training and Cognitive Remediation NCT03284060	Hôpital le Vinatier	N/A
Terminated	Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome NCT04639960	University of Geneva, Switzerland	N/A
Completed	Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric C NCT02895906	Aevi Genomic Medicine, LLC, a Cerecor company	Phase 1
Completed	Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome NCT04647500	University of Geneva, Switzerland	N/A
Recruiting	Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome NCT00556530	Albert Einstein College of Medicine	—
Completed	Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome NCT02460328	Mahidol University	—
Completed	Cognitive Remediation in 22q11DS NCT01781923	Duke University	N/A
Completed	Genetic Modifiers for 22q11.2 Syndrome NCT00916955	State University of New York - Upstate Medical University	—